Treatment of tardive dyskinesia with vitamin E. 1992

M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
Neuropsychiatry Branch, NIMH, Washington, D.C. 20032.

OBJECTIVE Vitamin E (alpha-tocopherol), a free-radical scavenger, has been reported to improve symptoms of tardive dyskinesia. The authors attempted to replicate this finding under more controlled conditions in a larger study group. METHODS Fifteen inpatients and six outpatients with tardive dyskinesia received up to 1600 IU/day of vitamin E for 6 weeks in a double-blind, placebo-controlled crossover study. Abnormal Involuntary Movement Scale (AIMS) examinations of these patients were videotaped and rated independently by two trained raters. Levels of neuroleptic medication and vitamin E were measured during both treatment periods. Eighteen patients who demonstrated high blood levels of vitamin E were included in the data analysis. RESULTS Vitamin E levels were significantly higher while the patients were receiving vitamin E than while they were receiving placebo. For all 18 patients, there were no significant differences between AIMS scores after receiving vitamin E and AIMS scores after receiving placebo. In agreement with previous studies, however, the nine patients who had had tardive dyskinesia for 5 years or less had significantly lower AIMS scores after receiving vitamin E than after receiving placebo. There were no changes in neuroleptic levels during vitamin E treatment. CONCLUSIONS Vitamin E had a minor beneficial effect on tardive dyskinesia ratings in a selected group of patients who had had tardive dyskinesia for 5 years or less. This effect was not due to an increase in blood levels of neuroleptic medications.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010808 Physical Examination Systematic and thorough inspection of the patient for physical signs of disease or abnormality. Physical Exam,Examination, Physical,Physical Examinations and Diagnoses,Exam, Physical,Examinations, Physical,Exams, Physical,Physical Examinations,Physical Exams
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001523 Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function. Mental Illness,Psychiatric Diseases,Psychiatric Disorders,Psychiatric Illness,Behavior Disorders,Diagnosis, Psychiatric,Mental Disorders, Severe,Psychiatric Diagnosis,Illness, Mental,Mental Disorder,Mental Disorder, Severe,Mental Illnesses,Psychiatric Disease,Psychiatric Disorder,Psychiatric Illnesses,Severe Mental Disorder,Severe Mental Disorders

Related Publications

M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
September 1993, The American journal of psychiatry,
M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
June 1993, The American journal of psychiatry,
M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
June 1993, The American journal of psychiatry,
M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
January 1997, Biological psychiatry,
M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
January 1993, Journal of postgraduate medicine,
M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
April 1990, The American journal of psychiatry,
M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
November 1999, The Annals of pharmacotherapy,
M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
March 1993, The Annals of pharmacotherapy,
M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
June 1995, Biological psychiatry,
M F Egan, and T M Hyde, and G W Albers, and A Elkashef, and R C Alexander, and A Reeve, and A Blum, and R E Saenz, and R J Wyatt
June 1998, Biological psychiatry,
Copied contents to your clipboard!